Reagents

Reagents HHS-NIH-NIDA-SSSA-PSOL-15-381 This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. This acquisition is being conducted in accordance with the procedures of FAR Part 13--Simplified Acquisition Procedures, FAR Subpart 13.5--Test Program for Certain Commercial Items, and FAR Part 12--Acquisition of Commercial Items. The solicitation number is HHS-NIH-NIDA-(SSSA)-PSOL-15-381 and the solicitation is issued as a PRE-SOLICITATION, NOTICE OF INTENT, to award a contract on a noncompetitive basis Promega Corporation 2800 Woods Hollow Road Madison, Wisconsin 53711. This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13--Simplified Acquisition Procedures, Subpart 13.5--Test Program for Certain Commercial Items, and Subpart 6.302-1, Only one responsible source and no other supplies or services will satisfy agency requirements, and is expected to exceed the simplified acquisition threshold. Contracts awarded using FAR Part 13--Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6--Competition Requirements. The non-competitive determination is based upon the market research conducted as prescribed in FAR Part 10--Market Research, specifically the results of market research concluded no other source of supply or service has access to the requirement in this acquisition. The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2005-83, dated August 3, 2015. The associated NAICS code for this requirement is 325413, In Vitro Diagnostic Substance Manufacturing, size standard 500 employees. The National Institutes of Health (NIH) is the nation's leading medical research agency and the primary Federal agency whose mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability, conducting, supporting and making medical discoveries that improve people's health and save lives. Purpose and Objectives: The Tox21 group of National Center for Advancing Translational Sciences (NCATS), Division of Preclinical Innovation (DPI) requires two reagents named "RealTime-Glo(TM) MC Cell Viability Assay" and "CellTox(TM) Green Express Cytotoxicity Assay" from Promega Corporation to screen Tox21 10k Library collections in a high-throughput format. The assay allows measure cytotoxicity and cell viability in real time. We have done online validation and started to screen Tox21 10k library compounds using this assay. To complete on-going screening projects, the purchase will be necessary to provide the supplies of the assays. Project Background: Measures of cell cytotoxicity and viability are critical in the cell-base assay. Our group developed a multiplex assay in a high throughput format by combining Promega's RealTime-Glo MC Cell Viability Assay and CellTox Green Express Cytotoxicity Assay to monitor both cytotoxicity and cell viability throughout the experiment during cell culture. Analysis of cytotoxicity in this format will allow determination of the rate at which compounds/drugs affect the cells. In addition, cytotoxicity and cell viability are usually tested separately in a traditional way. Therefore, this multiplex assay not only provided more valuable information, but it also can save time and supplies (e.g. plates, cell culture medium etc.). Project Requirements: Specifically, the NCATS requires the following: G8092 Caspase-Glo(R) 3/7 Assay, 100ml Qty 25 G8731 CellTox(TM) Green Express Cytotoxicity Assay Qty 30 G9713 RealTime-Glo(TM) MT Cell Viability Assay, 1000 RXN Qty 60 G8093 Caspase-Glo(R) 3/7 Assay, 10 x 10ml Qty 10 G9290 CytoTox-Glo(TM) Cytotoxicity Assay, 10ml Qty 15 G9292 CytoTox-Glo(TM) Cytotoxicity Assay, 2 x 50ml Qty 5 G7890 CytoTox-ONE(TM) Homogen Membrane Integrity Assay, 200-800 assa Qty 15 G7892 CytoTox-ONE(TM) Homogen Membrane Integrity Assay, HTP Qty 10 This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. Responses to this solicitation must include sufficient information to establish the interested parties' bona-fide capabilities of providing the product or service. The price quote shall include: unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s); product description; and any other information or factors that may be considered in the award decision. Such factors may include: past performance; special features required for effective program performance; trade-in considerations; probable life of the item selected as compared with that of a comparable item; warranty considerations; maintenance availability; and environmental and energy efficiency considerations. Respondents that believe that they are manufacturers or authorized resellers of the brand-name product specified in this announcement must provide, as part of their response: (a) product, catalog, model, and/or part number(s); (b) product description; (c) all relevant information and documentation that the item(s) offered meets the salient physical, functional, or performance characteristics as specified in the purchase description; quantity; estimated price or cost; shipping, handling, and/or installation charges; and delivery date after receipt of order. The following FAR provisions shall apply to this solicitation: 52.212-1, Instructions to Offerors--Commercial Items, 52.212-2, Evaluation--Commercial Items. Evaluation factors that will be used to evaluate the offer most advantageous to the Government, price and other factors considered, include ability to meet the technical requirements stated in this pre-solicitation and on basis of best value to the government. Offerors must include a completed copy of the provision at 52.212-3, Offeror Representations and Certifications Commercial Items, with their offer. The Clause at 52.212-4, Contract Terms and Conditions Commercial Items, applies to this acquisition and the Clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders Commercial Items applies to this acquisition. The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. In addition the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All Offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency. All responses must be received by September 17, 2015 at 4:00 pm, Eastern Standard Time (EST) and must reference solicitation number HHS-NIH-NIDA-SSSA-PSOL-15-381. Responses may be submitted electronically to contact@example.gov and to contact@example.gov or by U.S. mail to the National Institute of Drug Abuse (NIDA), Station Support / Simplified Acquisition Branch (SS/SA), 31 Center Drive, Building 31, Room 1B59, Bethesda, Maryland 20892-2080, Attention: Andrea McGee. Fax responses will be accepted at +1 (555) 000-0000. For information regarding this solicitation, contact Andrea McGee by email at contact@example.gov or by phone at +1 (555) 000-0000.